Literature DB >> 18334267

Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP.

V Fontana1, W Jy, E R Ahn, P Dudkiewicz, L L Horstman, R Duncan, Y S Ahn.   

Abstract

BACKGROUND: Splenectomy is frequently employed for therapeutic and diagnostic purposes in various clinical disorders. However its long-term safety is not well elucidated. Although risk of infection by encapsulated organisms is widely recognized, less well-known are risks of thrombosis and cardiovascular disease.
METHODS: We investigated levels of cell-derived microparticles (C-MP) in 23 splenectomized ITP (ITP-S) and 53 unsplenectomized ITP patients (ITP-nS). Assay of C-MP derived from platelets (PMP), leukocytes (LMP), red cells (RMP) and endothelial cells (EMP) were performed by flow cytometry. Coagulation parameters included PT, aPTT and activities of FVIII, IX and XI. Results of all measures were compared between the two groups, ITP-S vs ITP-nS.
RESULTS: Levels of all C-MP were higher in ITP-S than ITP-nS but only RMP and LMP reached statistical significance (p = 0.0035 and p < 0.0001, respectively). The aPTT was significantly shorter in ITP-S (p = 0.029). Interestingly, correlation analysis revealed that RMP, but not other C-MP, were associated with shortening of aPTT (p = 0.024) as well as with increased activities of factors VIII (p = 0.023), IX (p = 0.021) and XI (p = 0.0089).
CONCLUSIONS: RMP and LMP were significantly elevated in splenectomized compared to non-splenectomized ITP patients. This suggests that the spleen functions to clear procoagulant C-MP, and that elevation of C-MP might contribute to increased risk of thrombosis, progression of atherosclerosis and cardiovascular disease following splenectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334267     DOI: 10.1016/j.thromres.2007.12.022

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  15 in total

Review 1.  Extracellular vesicles and blood diseases.

Authors:  Shosaku Nomura
Journal:  Int J Hematol       Date:  2017-01-27       Impact factor: 2.490

Review 2.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

Review 3.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

4.  Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease.

Authors:  Eduard J van Beers; Marianne C L Schaap; René J Berckmans; Rienk Nieuwland; Augueste Sturk; Frederiek F van Doormaal; Joost C M Meijers; Bart J Biemond
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

5.  Acid sphingomyelinase is activated in sickle cell erythrocytes and contributes to inflammatory microparticle generation in SCD.

Authors:  Anthony O Awojoodu; Philip M Keegan; Alicia R Lane; Yuying Zhang; Kevin R Lynch; Manu O Platt; Edward A Botchwey
Journal:  Blood       Date:  2014-07-29       Impact factor: 22.113

Review 6.  Splenectomy in zebrafish: a new model for immune thrombocytopenia.

Authors:  Uvaraj P Radhakrishnan; Ayah Al Qaryoute; Revathi Raman; Pudur Jagadeeswaran
Journal:  Platelets       Date:  2021-02-04       Impact factor: 3.862

7.  Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.

Authors:  Philip Yi Choi; Eileen Merriman; Ashwini Bennett; Anoop K Enjeti; Chee Wee Tan; Isaac Goncalves; Danny Hsu; Robert Bird
Journal:  Med J Aust       Date:  2021-10-10       Impact factor: 12.776

8.  Platelet count kinetics following interruption of antiretroviral treatment.

Authors:  Eva Zetterberg; Jacqueline Neuhaus; Jason V Baker; Charurut Somboonwit; Josep M Llibre; Adrian Palfreeman; Maria Chini; Jens D Lundgren
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

9.  Splenectomy is modifying the vascular remodeling of thrombosis.

Authors:  Maria K Frey; Sherin Alias; Max P Winter; Bassam Redwan; Gerald Stübiger; Adelheid Panzenboeck; Arman Alimohammadi; Diana Bonderman; Johannes Jakowitsch; Helga Bergmeister; Valery Bochkov; Klaus T Preissner; Irene M Lang
Journal:  J Am Heart Assoc       Date:  2014-02-28       Impact factor: 5.501

Review 10.  Eltrombopag for the treatment of aplastic anemia: current perspectives.

Authors:  Su Han Lum; John D Grainger
Journal:  Drug Des Devel Ther       Date:  2016-09-13       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.